Start in CHO, Stay in CHO

Our view is that there is no need to involve HEK293 transient in the development of protein and antibodies. With superior CHO transient, HEK293 offers no advantage. If eventually the product will be made in a CHO stable cell line, we see no reason why not start the first transient production CHO and stay in CHO.

LakePharma CHO Platforms

Download flyer: Large-scale Ab Production: Hybridoma or Recombinant?

Click here to learn more about our proprietary TunaCHO platform and detailed services.  

Click here to learn more about LakePharma's CHO-GSN platform

Download our CHO-GSN Presentation by clicking here and our TunaCHO presentation by clicking here